Genital levels of soluble immune factors with anti-HIV activity may correlate with increased HIV susceptibility

AIDS

Volumn 22, Issue 15, 2008, Pages 2049-2051

  Kaul, Rupert ^a,b,d,f   Rebbapragada, Anuradha ^a,e   Hirbod, Taha ^a   Wachihi, Charles ^b   Ball, Terry B ^c,e   Plummer, Francis A ^c   Kimani, Joshua ^b,c   Jaoko, Walter ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e ONTARIO MINISTRY OF HEALTH AND LONG TERM CARE   (Canada)

^f Clinical Science Division   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD209 ANTIGEN; CD3 ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; RANTES; T6 ANTIGEN; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHLAMYDIA TRACHOMATIS; FEMALE; FEMALE GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; LAVAGE; LETTER; MAJOR CLINICAL STUDY; NEISSERIA GONORRHOEAE; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; TRICHOMONAS VAGINALIS; UTERINE CERVIX; VAGINA; VAGINITIS;

CHEMOKINE CCL5; DISEASE SUSCEPTIBILITY; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; PROSTITUTION;

EID: 53549115621     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328311ac65     Document Type: Letter

References (9)

1. Spear GT, Sha BE, Saarloos MN, Benson CA, Rydman R, Massad LS, et al. Chemokines are present in the genital tract of HIV-seropositive and HIV-seronegative women: correlation with other immune mediators. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:454-459.
2. Iqbal SM, KauI R. Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol 2008; 59:44-54.
3. van de Wijgert JH, Shattock RJ. Vaginal microbicides: moving ahead after an unexpected setback. AIDS 2007; 21:2369-2376.
4. Hirbod T, Nilsson J, Andersson S, Uberti-Foppa C, Ferrari D, Manghi M, et al. Upregulation of interferon-a and RANTES in the cervix of HIV-1-seronegative women with high-risk behavior. J Acquir Immune Defic Syndr 2006; 43:137-143.
5. lqbal SM, Ball TB, Kimani J, Kiama P, Thottingal P, Embree JE, et al. Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J Infect Dis 2005; 192:728-738.
6. Novak RM, Donoval BA, Graham P), Boksa LA, Spear G, Hershow RC, et al. Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol 2007; 14:1102-1107.
7. Rebbapragada A, Wachihi C, Pettengell C, Sunderji S, Huibner S, Jaoko W, et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS 2007;21:589-598.
8. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE 2008; 3:e1474.
9. Keller MJ, Herold BC. Impact of microbicides and sexually transmitted infections on mucosal immunity in the female genital tract. Am J Reprod Immunol 2006; 56:356-363.